Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

被引：0
|
作者：
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William G.
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Jones, Jeffrey
Iyer, Swami P.
Jones, Surai
Jiang, Yanwen
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
430
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Cho, Sang Kyu
    Manzoor, Beenish S.
    Sail, Kavita R.
    Parise, Helene
    Ravelo, Arliene
    Shapouri, Sheila
    Kapustyan, Tatyana
    Sharmokh, Simon
    Virabhak, Suchin
    Davids, Matthew S.
    Johnson, Scott
    PHARMACOECONOMICS, 2020, 38 (09) : 941 - 951
  • [32] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Sang Kyu Cho
    Beenish S. Manzoor
    Kavita R. Sail
    Hélène Parisé
    Arliene Ravelo
    Sheila Shapouri
    Tatyana Kapustyan
    Simon Sharmokh
    Suchin Virabhak
    Matthew S. Davids
    Scott Johnson
    PharmacoEconomics, 2020, 38 : 941 - 951
  • [33] Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Dixon, Mark
    Bahlo, Jasmin
    Warburton, Simon
    Kipps, Thomas J.
    Weinkove, Robert
    Robinson, Sue
    Dreyling, Martin H.
    Opat, Stephen
    Owen, Carolyn J.
    Lopez, Javier
    Humphrey, Kathryn
    Humerickhouse, Rod A.
    Tausch, Eugen
    Eichhorst, Barbara
    Wendtner, Clemens-M.
    Langerak, Anton W.
    van Dongen, Jacques J. M.
    Ritgen, Matthias
    Boettcher, Sebastian
    Stilgenbauer, Stephan
    Goede, Valentin
    Mobasher, Mehrdad
    Hallek, Michael
    BLOOD, 2016, 128 (22)
  • [34] Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
    Leblond, Veronique
    Aktan, Melih
    Ferra Coll, Christelle M.
    Dartigeas, Caroline
    Kisro, Jens
    Montillo, Marco
    Raposo, Joao
    Merot, Jean-Louis
    Robson, Susan
    Gresko, Ekaterina
    Bosch, Francesc
    Stilgenbauer, Stephan
    Foa, Robin
    HAEMATOLOGICA, 2018, 103 (11) : 1889 - 1898
  • [35] Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study
    Flinn, Ian W.
    Andorsky, David
    Melear, Jason
    Manda, Sudhir
    Anz, Bertrand, III
    Kolibaba, Kathryn
    Yimer, Habte
    Burke, John M.
    Fanning, Suzanne
    Courtright, Jay
    Islas-Ohlmayer, Miguel
    Kambhampati, Suman
    Vizkelety, Tamas
    Pesko, John
    Chyla, Brenda
    Jiang, Dingfeng
    Sharman, Jeff P.
    BLOOD, 2021, 138 : 3725 - +
  • [36] Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
    Deng, Rong
    Gibiansky, Leonid
    Lu, Tong
    Li, Xiaobin
    Lu, Dan
    Li, Chunze
    Girish, Sandhya
    Wang, Jue
    Boyer, Michelle
    Shankar, Noopur
    Humphrey, Kathryn
    Freise, Kevin J.
    Salem, Ahmed Hamed
    Seymour, John F.
    Kater, Arnon P.
    Miles, Dale
    LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 56 - 65
  • [37] Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
    Danilov, Alexey
    Yimer, Habte A.
    Boxer, Michael
    Burke, John M.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Trask, Peter C.
    Masaquel, Anthony S.
    Sharman, Jeff P.
    BLOOD, 2019, 134
  • [38] Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine
    Danilov, Alexey, V
    Yimer, Habte A.
    Boxer, Michael A.
    Burke, John M.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Trask, Peter C.
    Masaquel, Anthony S.
    Sharman, Jeff P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (02): : 121 - 128
  • [39] Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
    Sharman, Jeff P.
    Burke, John M.
    Yimer, Habte A.
    Boxer, Michael A.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Danilov, Alexey
    BLOOD, 2019, 134
  • [40] Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study
    Laurenti, Luca
    Vannata, Barbara
    Innocenti, Idanna
    Autore, Francesco
    Ghio, Francesco
    Cecconi, Nadia
    Pitini, Vincenzo
    Mondello, Patrizia
    Lanza Cariccio, Maria Rosa
    Gozzetti, Alessandro
    D'Arena, Giovanni
    Murru, Roberta
    Piccirillo, Nicola
    Leone, Giuseppe
    Sica, Simona
    BLOOD, 2013, 122 (21)
12345